Merck Animal Health and Rapid Genomics Sign Exclusive Agreement on Vaccine Verification (Merck Animal Health)

Merck Animal Health and Rapid Genomics Sign Exclusive Agreement on Vaccine Verification

Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, announced a collaboration agreement with UF Innovate | The Hub anchor client Rapid Genomics which grants the company exclusive rights to Rapid Genomics’ vaccination verification tool, Viral Flex-Seq®. This tool will be utilized in combination with Merck Animal Health’s Innovax® range of vaccines, including Innovax®-ND-IBD, a unique vaccine that provides long-term protection against three infectious poultry diseases, Newcastle Disease (ND), Infectious Bursal Disease (IBD) and Marek’s Disease (MD), in a single dose. The collaboration was announced at the 2019 International Production & Processing Expo (IPPE) being held in Atlanta, Georgia, from February 12-14, 2019.

“This partnership will bring together Merck Animal Health’s unique broad vaccine product line and Rapid Genomics’ innovative vaccination verification test, to optimize and enhance disease outbreak management in poultry for improved animal health and welfare,” said Taylor Barbosa, DVM, Ph.D., ACPV, Executive Director, Global Poultry Marketing, Merck Animal Health. “As the poultry industry grows, there is an increased need for improving disease control to optimize productivity and we are committed to growing with the industry to bring innovative solutions to our customers.”

Learn more about Merck Animal Health and Rapid Genomics Sign Exclusive Agreement on Vaccine Verification.
X